The risks of investing in Johnson & Johnson (JNJ)

From the Sep 26, 2026 report · Read the full report

Risks flagged in the analysis

Rising interest rates could pressure JNJ's high price-to-book ratio (7.69x).
Regulatory risks in the pharmaceutical sector, including drug pricing reforms, may impact profitability.
The company's PEG ratio of 2.84 suggests overvaluation relative to growth, requiring careful valuation assessment.
A potential downward breakout below the Bollinger Lower Band ($262.83) could signal weakening momentum.
Litigation exposure, including opioid and infrastructure suits, remains a persistent risk factor.

Bear case

The PEG ratio of 2.84 suggests potential overvaluation relative to growth, cautioning against buying at current levels.
The MACD histogram shows declining momentum (-0.26), indicating slowing upward momentum and potential near-term consolidation.
A current ratio of 1.09 is marginally tight, raising concerns about short-term liquidity for aggressive credit analysts.
Rising Treasury yields (10Y at 5.18%) pressure high valuation stocks like JNJ, which trades at a rich P/E of 31.50 TTM.
Patent cliff risks and litigation exposure, noted in news coverage, present potential headwinds to future growth.

Risk in numbers

Beta: 0.24
Debt / equity: 57.7
Annual volatility: 18.9%
Largest fall in 12 months: -11.0%

52-week range

$177.32$281.07

Frequently asked questions

What are the risks of investing in JNJ?

Rising interest rates could pressure JNJ's high price-to-book ratio (7.69x). Regulatory risks in the pharmaceutical sector, including drug pricing reforms, may impact profitability. The company's PEG ratio of 2.84 suggests overvaluation relative to growth, requiring careful valuation assessment.

Sources: Yahoo Finance (prices, financial statements and analysts' estimates) and the U.S. Treasury (10-year yield). Indicators and valuation are computed without AI.

AI-generated informational content. Not financial advice or a personalised investment recommendation. Investing involves risk, including loss of capital.

Every week, in your inbox

Rating changes, the highest-conviction stocks and the week's best research. Free.